Evolent Health, Inc. (NYSE:EVH - Get Free Report) traded up 5% on Tuesday . The company traded as high as $8.63 and last traded at $8.59. 501,402 shares changed hands during trading, a decline of 79% from the average session volume of 2,414,384 shares. The stock had previously closed at $8.18.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the stock. UBS Group lifted their price objective on shares of Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Friday, May 9th. JMP Securities restated a "market outperform" rating and set a $13.00 price objective on shares of Evolent Health in a research note on Monday, April 28th. Truist Financial cut their price objective on shares of Evolent Health from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. Needham & Company LLC restated a "buy" rating and set a $15.00 price objective on shares of Evolent Health in a research note on Tuesday, May 13th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Evolent Health from $13.00 to $12.00 and set an "overweight" rating on the stock in a research note on Monday, March 10th. One investment analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Evolent Health currently has a consensus rating of "Buy" and a consensus price target of $17.79.
Read Our Latest Report on Evolent Health
Evolent Health Trading Up 4.0%
The company has a fifty day simple moving average of $8.91 and a 200-day simple moving average of $9.88. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58. The stock has a market cap of $998.49 million, a price-to-earnings ratio of -10.37 and a beta of 0.87.
Evolent Health (NYSE:EVH - Get Free Report) last released its earnings results on Thursday, May 8th. The technology company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.02). Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. The business had revenue of $483.65 million for the quarter, compared to analysts' expectations of $460.15 million. During the same period last year, the firm earned $0.34 EPS. The company's revenue was down 24.4% compared to the same quarter last year. On average, research analysts forecast that Evolent Health, Inc. will post 0.08 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Evolent Health
Institutional investors and hedge funds have recently bought and sold shares of the business. Pilgrim Partners Asia Pte Ltd purchased a new position in Evolent Health during the 4th quarter valued at about $26,000. Banque Cantonale Vaudoise bought a new stake in shares of Evolent Health in the 1st quarter valued at approximately $25,000. AlphaQuest LLC grew its stake in shares of Evolent Health by 21,650.0% in the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock valued at $34,000 after buying an additional 3,031 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Evolent Health by 90.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock valued at $56,000 after buying an additional 2,358 shares in the last quarter. Finally, Strs Ohio bought a new stake in shares of Evolent Health in the 1st quarter valued at approximately $47,000.
Evolent Health Company Profile
(
Get Free Report)
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evolent Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolent Health wasn't on the list.
While Evolent Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
